As of Jan 18
| -0.16 / -2.29%|
The 4 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 8.75, with a high estimate of 12.00 and a low estimate of 7.00. The median estimate represents a +28.30% increase from the last price of 6.82.
The current consensus among 5 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.